Bloomberg Stock Movers
2026-08-03 · Hosted by — · Bloomberg / iHeartMedia
Executive Summary
Monday's Stock Movers roundup led with a potential mega pharma merger: Bristol Myers Squibb and AstraZeneca are in early-stage talks to combine, which would rank as the largest pharma deal ever, though AstraZeneca shares fell about 4.5% in pre-market trade as analysts questioned the strategic logic given AstraZeneca's strong standalone growth. The conversation then turned to chip stocks recovering from a rough July — the Philadelphia semiconductor index posted its worst month since 2008, entering bear-market territory, with Intel hit hardest while Nvidia finished roughly flat, showing relative resilience.
Key Stories & Changes
1. Bristol Myers Squibb / AstraZeneca Merger Talks
The companies are in early-stage discussions about a combination that would be the largest pharma deal ever.
AstraZeneca shares fell approximately 4.5% in pre-market trading on the news.
Analysts questioned whether the deal makes strategic sense given AstraZeneca's fast standalone growth trajectory.
It remains unclear whether discussions will continue or result in an actual transaction.
2. Semiconductor Sector Recovering from Worst Month Since 2008
The Philadelphia Stock Exchange Semiconductor Index posted its worst month since 2008 in July, entering bear-market territory (down more than 20% from its late-June record high).
Intel was the worst-performing major chip name in July.
Nvidia finished roughly flat for the month, a relative outperformance versus peers amid the sector-wide selloff.
Intel shares were down about 0.7% in pre-market trade at the time of the segment.
AZN: AstraZeneca — ~-4.5% (pre-market) — Early-stage merger talks with Bristol Myers Squibb; analysts skeptical of deal logic
NVDA: Nvidia — ~Flat (July) — Outperformed semiconductor peers during July's sector-wide selloff
INTC: Intel — ~-0.7% (pre-market) — Worst-performing major chip name in July amid broader semiconductor bear market
SPACEX: SpaceX — Down ~30% since IPO — First public earnings report due Tuesday after the bell; lock-up expiration adds volatility risk
3. SpaceX's First Public Earnings Report Ahead
SpaceX reports Tuesday after the bell — its first earnings release as a public company.
Shares are down roughly 30% since going public.
The report coincides with the expiration of an insider-owned stock lock-up, expected to add volatility.
Bloomberg's Lauren Grouchy noted unprecedented reporting access to SpaceX given its historically private status; focus areas include Starship progress, Starlink, and AI infrastructure investment.
Uncertain whether Elon Musk will personally join the earnings call.
Trends Identified
1. Pharma Consolidation Speculation Amid Growth Divergence
The AstraZeneca/Bristol Myers Squibb talks reflect ongoing consolidation pressure in pharma, but the stock's negative reaction suggests investors are skeptical that scale-driven M&A benefits a company already growing quickly on its own.
2. Semiconductor Sector Bifurcation Persists Into August
July's steep chip-sector selloff (worst since 2008) shows continued divergence between AI-exposed leaders like Nvidia, which held up better, and legacy players like Intel, which bore the brunt of the decline — a pattern likely to continue shaping sector positioning into the new month. ---
Sentiment Analysis
Overall Market Sentiment: Cautious, Watching Catalysts
Sentiment was mixed heading into the new trading month, with skepticism around the pharma merger rationale and lingering caution in semiconductors following a historically bad July, balanced against anticipation for SpaceX's high-profile earnings debut.
Risk Factors Highlighted
Merger uncertainty: AstraZeneca/BMS talks are early-stage and may be delayed or fall apart entirely.
Semiconductor sector volatility: Bear-market territory reached in July raises the risk of continued instability into August.
SpaceX lock-up expiration: Insider share unlocks around earnings could add significant downside pressure or volatility.
SpaceX post-IPO underperformance: Down roughly 30% since its public debut, raising questions about investor confidence heading into its first earnings report.
This episode was covered in today's [The Market Signal — 2026-08-03](https://marketsignal.beehiiv.com/p/the-market-signal-2026-08-03), a cross-source synthesis of multiple podcast reports.